title: Hoarseness after metastatic colon cancer treatment.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland.
authors.forename: Andria M
authors.initials: AM
authors.lastname: Caruso
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle.
authors.forename: Tanya K
authors.initials: TK
authors.lastname: Meyer
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Washington School of Medicine, Seattle3Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Bethesda, Maryland.
authors.forename: Clint T
authors.initials: CT
authors.lastname: Allen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000473:pathology; D055154:Dysphonia / Q000209:etiology*; D005260:Female; D006685:Hoarseness / Q000209:etiology*; D006801:Humans; D007828:Laryngoscopy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced; D014827:Vocal Cords / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab